home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 03/25/22

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - Long COVID, the newest target of vaccine and drug developers

Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long CO...
AIM - AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-? with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Rosw

OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...

AIM - AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

OCALA, Fla., March 23, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...

AIM - AIM Immunotech stock soars 25% as FDA lifts hold, paving way for pancreatic cancer study

AIM ImmunoTech (NYSE:AIM) said the U.S. Food and Drug Administration lifted its clinical hold on an investigational new drug (IND) application allowing the company to begin a phase 2 study of Ampligen for locally advanced pancreatic cancer (AMP-270). The AMP-270 trial, which is expected to be...
AIM - AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a single-center named patient program, treatment with Ampligen following FOLFIRINOX was as...

AIM - AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...

AIM - AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
AIM - AIM ImmunoTech's Ampligen helps improve survival of pancreatic cancer patients in study

AIM ImmunoTech (NYSE:AIM) said Ampligen following FOLFIRINOX, a chemotherapy combination, showed improved survival rates in patients with pancreatic cancer compared to matched controls of patients who did not receive Ampligen. Ampligen (rintatolimod) was evaluated as a monother...

AIM - AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer

Ampligen ® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center Treatment with Ampligen following FOLFIRINOX was asso...

AIM - AIM Immunotech announces sale of New Brunswick, New Jersey facility

AIM ImmunoTech (NYSE:AIM) announces strategic sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9M. The Company will retain access to space in the New Brunswick facility for activities related to Alferon-N and also intends to lease additi...
Previous 10 Next 10